These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 33630072)

  • 41. Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD.
    Akizawa T; Iwasaki M; Otsuka T; Yamaguchi Y; Reusch M
    Kidney Int Rep; 2021 Jul; 6(7):1810-1828. PubMed ID: 34307976
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Expert Opin Pharmacother; 2022 Jan; 23(1):19-28. PubMed ID: 34686069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
    Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
    Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness.
    Liu J; Li S; Yang F; Li T; Li R; Waheed Y; Meng C; Li S; Liu K; Tong Y; Xu H; Tian C; Zhou X
    Korean J Intern Med; 2024 May; 39(3):488-500. PubMed ID: 38649158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Roxadustat and Oral Iron Absorption in Chinese Patients with Anemia of Chronic Kidney Disease: A Randomized, Open-Label, Phase 4 Study (ALTAI).
    Wu H; Cheng H; Wang C; Yao L; Qin S; Zuo L; Hu Z; Zhang C; Wu Y; Hofherr A; Mohan K; Rush S; Li X
    Adv Ther; 2024 Mar; 41(3):1168-1183. PubMed ID: 38280066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
    Zhou Q; Mao M; Li J; Deng F
    Ren Fail; 2023 Dec; 45(1):2195011. PubMed ID: 37489561
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials.
    Luo X; Li G; Yang H; Chen L; Gao Y; Cong J; Luo H; Zhang W
    BMC Nephrol; 2024 Feb; 25(1):47. PubMed ID: 38311719
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis.
    Tian L; Wang M; Liu M; Pang Y; Zhao J; Zheng B; Wang Y; Zhao W
    Ren Fail; 2024 Dec; 46(1):2313864. PubMed ID: 38345037
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.
    Akizawa T; Tanaka-Amino K; Otsuka T; Yamaguchi Y
    Am J Nephrol; 2021; 52(9):702-713. PubMed ID: 34628408
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Roxadustat regulates iron metabolism in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A meta-analysis.
    Hou YP; Wang C; Mao XY; Zhang MZ; Li B
    J Formos Med Assoc; 2022 Nov; 121(11):2288-2299. PubMed ID: 35871036
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis patients with renal anemia affected by the COVID-19 pandemic: a retrospective study.
    Bao L; Bian X; Zhang A; Huang J; Ren L; Luo C
    Ann Palliat Med; 2022 Jun; 11(6):2017-2024. PubMed ID: 35817736
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
    Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
    Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical effect of roxadustat vs. erythropoietin in non-dialysis CKD with diabetes: a single center propensity score matching analysis.
    Jin C; Ren Y; Wang M; Hu X; Shang Y; Li Y; Zhu B; He Q; Shao L
    Int Urol Nephrol; 2024 Aug; 56(8):2683-2693. PubMed ID: 38489143
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin.
    Yang X; Zhao B; Wang J; Wang L; Tao M; Lu J; Lin J; Sun J; Wang R
    Ren Fail; 2021 Dec; 43(1):1428-1436. PubMed ID: 34657570
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Prospective, Self-Controlled Pilot Study of the Efficacy of Roxadustat for Erythropoietin Hyporesponsiveness in Patients Requiring Chronic Ambulatory Peritoneal Dialysis.
    Chen J; Li Z; Zhang H; Hu J; Wang J; Zhou H; Liu Y; Liu J; Yi B; Zhang W
    J Ren Nutr; 2022 Sep; 32(5):595-604. PubMed ID: 34756787
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a health economic model to evaluate the cost-effectiveness of roxadustat in treating anemia associated with non-dialysis-dependent chronic kidney disease.
    Mata Lorenzo M; Ali M; Mealing S; Moss J
    J Med Econ; 2023; 26(1):1250-1260. PubMed ID: 37752891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel scenario in the therapeutic management of anemia of chronic kidney disease: placement and use of roxadustat.
    Locatelli F; Ravera M; Esposito C; Grandaliano G; Gesualdo L; Minutolo R
    J Nephrol; 2024 May; 37(4):1107-1119. PubMed ID: 38189866
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Whether Prolyl Hydroxylase Blocker-Roxadustat-In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
    Grzeszczak W; Szczyra D; Śnit M
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33567688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.